New drug tested for tough bone cancer after other treatments fail
NCT ID NCT03514407
Summary
This early-stage study tested the safety and initial effects of an experimental drug called INCB059872 in 25 people with advanced Ewing sarcoma, a rare bone and soft tissue cancer. Participants had cancer that returned or didn't respond to standard treatments and had no other curative options. The main goal was to see how well the drug was tolerated and if it showed any signs of shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Hospital Clínico San Carlos
Madrid, 28040, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Istituto Ortopedico Rizzoli
Bologna, 40136, Italy
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic Jacksonville - PPDS
Jacksonville, Florida, 32224, United States
-
Ospedale Pediatrico Bambino Gesu IRCCS
Rome, 00146, Italy
-
Policlinico Sant'orsola-Malpighi
Bologna, 40138, Italy
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
UCLA Jonsson Comprehensive Cancer
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.